ArticleBMC pregnancy and childbirth2026
The association of the ALBI score with disease severity and perinatal outcomes in the preeclampsia spectrum.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to investigate the association between the albumin–bilirubin (ALBI) score and disease severity across the preeclampsia spectrum and to evaluate its relationship with perinatal outcomes, with particular emphasis on differences according to gestational age.
methodsIn this retrospective cross-sectional study, medical records of 370 pregnant women diagnosed with preeclampsia between June 2021 and June 2025 were analyzed. Patients were stratified by gestational age at delivery (< 34 weeks and ≥ 34 weeks) and by disease severity (mild-to-moderate preeclampsia vs. severe preeclampsia). Maternal biochemical, hematological, and inflammatory parameters were recorded, and the ALBI score was calculated using serum albumin and total bilirubin levels. Perinatal outcomes included birth weight, Apgar scores, umbilical cord blood gas parameters, admission to the Neonatal Intensive Care Unit (NICU), and length of NICU stay. Receiver operating characteristic analyses were performed to assess the discriminative performance of the ALBI score.
resultsThe ALBI score was significantly higher in severe preeclampsia regardless of gestational age and showed superior discriminative performance compared with inflammatory indices, particularly in early-onset disease (< 34 weeks; AUC = 0.702). Higher ALBI scores were associated with adverse perinatal outcomes, including lower birth weight and increased NICU admission. In contrast, inflammatory indices (NLR, PLR, LMR, and SII) did not demonstrate clinically meaningful discrimination of disease severity or neonatal risk. Gestational age at delivery was the primary determinant of NICU length of stay.
conclusionsThe ALBI score is a robust, low-cost, and easily applicable biomarker that reflects biochemical disease severity and perinatal risk across the preeclampsia spectrum, particularly in early-onset severe preeclampsia. Prospective multicenter studies are required to confirm its clinical utility and define its role in future risk stratification algorithms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.